Author of

• 10720

  +

  P1.09 - Poster Session 1 - Combined Modality (ID 212)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Combined Modality
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10737

    +

    P1.09-017 - Continuous low dose temozolamide in Brain metastasis from Lung cancer (ID 2054)

    09:30 - 09:30  |  Author(s): T. Shahid
    • Abstract

    Background
    Metastasis of Lung cancer to Brain is associated with poor prognosis despite aggressive treatment. Available treatment options are limited beside radiotherapy as most drugs do not penetrate the blood brain barrier. Temozolamide has a good safety profile and crosses the blood brain barrier. One of the novel methods of delivering temozolamide is to use metronomic dosing which also has anti angiogenic properties, other than cytotoxic properties.

    Methods
    Eligible patients had to have confirmed Non Small Cell Lung Cancer (NSCLC) with no prior radiotherapy or radio-surgery for brain metastasis; with multiple brain metastasis. All patients were treated with Temozolamide 20mg in empty stomach twice a day continuously. Radiation was given to these patients as standard procedures. This was compared only to standard whole brain radiation. All patients continued on standard planned chemotherapy which was paclitaxel + carboplatinum and patients who had received Temozolamide were continued either till progression or unacceptable toxicity.

    Results
    41 patients - 24 men and 16 women with proven advanced Non Small Cell Lung Cancer (NSCLC) who were on treatment and developed brain metastasis, which was not operable or amicable to stereotactic radiotherapy.

    	Radiotherapy (n=20)	Radiotherapy & Low Dose Temozolamide (n=21)
    Median Karnofsky Score	> 60	> 60
    Response Rate	7 (35%)	12 (57%)
    Complete Response	1 (5%)	5 (24%)
    Partial Response	4 (20%)	7 (33%)
    Stable Disease	3 (15%)	3 (14%)
    1 year survival rate	6 (30%)	14 (67%)
    Median Overall Survival	9.2months	17.6months
    Thrombocytopenia Grade III/IV	3 (15%)	5 (24%)
    Neutropenia Grade III/IV	1 (5%)	2 (10%)
    Anemia Grade III/IV	3 (15%)	6 (29%)

    Conclusion
    Metronomic dosing of temozolamide with concurrent whole brain radiation is an effective option in treatment of brain metastasis from Non Small Cell Lung Cancer (NSCLC). The median survival time is almost doubled. Side-effects are manageable.

• 12409

  +

  P3.03 - Poster Session 3 - Technology and Novel Development (ID 152)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12411

    +

    P3.03-002 - Heterogenity of Adeno carcinoma of Lung - change in Immunohistochemistry and histopathology chacter in patients treated with chemotherapy or EGFR-TKIs (ID 1356)

    09:30 - 09:30  |  Author(s): T. Shahid
    • Abstract

    Background
    Adenocarcinoma of the lung is a heterogenous group of disease. Even within the same patient, the tumor may show, various patterns of histopathology. In fact published data suggest that only 1/3rd of lung cancer are homogenous. Although known this factor is not taken into account in treatment planning and management. It is also known that treatment induces heterogenity and change in character of the tumor.

    Methods
    46 patients of Stage IV Adenocarcinoma of Lung were studied. All patients were confirmed as Adenocarcinoma by doing IHC TTF p63. All slides were viewed by two pathologists and all patients had EGFR mutation done.IHC marker for neuro-endocrine differentiation was done i.e. Chromogranin-A and Synaptophysin. Patients were treated with chemotherapy or EGFR-TKI. Patients were re-biopsied on progression. The same set of IHC studies was done.

    Results
    

    	IHC marker for adenocarcinoma	IHC marker for squamous cell	Neuro-endocrine marker
    n=46
    Pre-chemotherapy/TKI	41 (89%)	15 (32%)	17 (37%)
    Post-chemotherapy/TKI	25 (54%)	25 (54%)	29 (63%)
    n=18
    Pre TKI	16 (89%)	5 (28%)	4 (22%)
    Post TKI	8 (44%)	9 (50%)	14 (78%)
    n=28
    Pre-chemotherapy	25 (89%)	10 (36%)	13 (46%)
    Post-chemotherapy	17 (61%)	16 (57%)	15 (54%)

    Median duration of chemotherapy - 10 months Median duration of TKI - 16 months Change in character on IHC - seen in approximately 30% patients Infact change in post TKI occurring in upto 50% of patients with gain in Small Cell characters. Of the 50% patients who gained i.e. 10 patients - 7 of them also showed microscopic features of Small Cell Carcinoma of Lungs.

    Conclusion
    The study suggests that patients with advanced lung cancer have benefit from chemotherapy and TKI. On treatment and on progression there is a change in IHC and histopathology character in the patients. It occurs in close to 40% in such patients. These changes also call for changes in treatment. Hence re-biopy in such patients is essential.